Drug intelligence / Profile preview

Abisave-FLO

Development stage: Unknown
Lead developer: Cam Neuro Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Abisave-FLO** is an oral fixed-dose respiratory medicine marketed by Cam Neuro Pharma containing acebrophylline 100 mg and N-acetylcysteine 600 mg per tablet. Acebrophylline is a bronchodilator, airway mucus regulator, and anti-inflammatory agent, while N-acetylcysteine is a thiol mucolytic that decreases mucus viscosity and also supports antioxidant glutathione pathways. The combination is used for obstructive respiratory conditions associated with mucus hypersecretion, including chronic obstructive pulmonary disease and chronic bronchitis. ([camneuropharma.com](https://www.camneuropharma.com/products/ourproducts))

Brand names: Abisave-FLO
Other names: acebrophylline + N-acetylcysteineacebrophylline + N-acetylcysteine tablets

Targets

PDE (Phosphodiesterase family)GSH (Glutathione)

Beyond the preview

Go deeper on Abisave-FLO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abisave-FLO.

Explore the full profile